Slides
Page 1
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —1 Grow with GinkgoJ.P. Morgan Healthcare ConferenceJason KellyCo-Founder & CEOJanuary 16, 2024 10:30AM Pacific1
Page 2
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —2Forward-Looking StatementsThis presentation, the conference call and webcast (together, the “presentation”) contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our balance sheet and cash runway, current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining adjusted EBITDA breakeven and profitability, the success of our new offerings and anticipated impacts on our results, our planned reduction in workforce and anticipated impacts thereof, the timing and structuring of our planned site consolidation and the potential financial impact thereof, opportunities for and timing of increased operational efficiency and the expected impact on our operational expenditures, potential customer success, including successful application of our offerings by our customers, the capabilities and potential operational and financial success of our partnerships and collaborations, and expected timing thereof, expectations with regard to revenue, the nature of such revenue and any related downstream value share associated with such revenue, funding that is contingent upon Ginkgo’s achievement of milestones, expenses, including our stock-based compensation expenses, our full year 2024 outlook, the expansion, timing and potential capabilities of our biosecurity monitoring, surveillance and detection systems, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development or commercialization success of our customers, and (xi) the potential negative impact on our business of our planned reduction in force or the failure to realize the anticipated savings associated therewith. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.Industry and Market DataIn this presentation, Ginkgo relies on and refers to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo management’s estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information, and Ginkgo has not independently verified the accuracy or completeness of the information provided by the third-party sources.TrademarksThis presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Disclaimer 2
Page 3
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —3 OUR MISSIONMake biology easier to engineerOUR MISSIONMake biology easier to engineer
Page 4
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —41 2 3Restructuring in mid-2024 has greatly reduced cash opexGinkgo continues to grow our revenue in biopharmaExpansion into direct sales of life science tools & services is opening new markets for our transformational tech 4 We believe…
Page 5
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —51 2 3Restructuring in mid-2024 has greatly reduced cash opexGinkgo continues to grow our revenue in biopharmaExpansion into direct sales of life science tools & services is opening new markets for our transformational tech 5 We believe…
Page 6
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —6Ginkgo continued to grow our biopharma business in 2024 More than 40 ongoing biopharma partnered programs: More than 90 ongoing industrial biotech, food & ag, consumer, and government partnered programs:
Page 7
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —7 Completion of the first milestone of the previously announced partnership with MerckAs part of this milestone completion, Ginkgo received a research milestone payment of $9 million in cash in Q4 2024 With Stage 1 complete, Merck and Ginkgo will move to Stage 2 focused on continuing to improve the production process Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics ManufacturingWe're excited to achieve the first milestone of our collaboration with Merck and continue our work to improve biologic manufacturing production. It’s very meaningful when our team can drive impactful and technically innovative work like this, especially when we’re working shoulder-to-shoulder with counterparts like the team at Merck.As we go into the next phase of this project, we’ll continue to deploy the strain engineering, high-throughput screening and process development capabilities, as well as the assets and know-how that make Ginkgo a unique and powerful partner to top pharmaceutical companies.November 12, 2024 Ginkgo continues to deliver for its customers as it reaches a major research milestone with Merck1 32 JASON KELLYCEO, co-founder
Page 8
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —8Novo Nordisk represents a model for what we can accomplish with key customers as we demonstrate our capabilitiesGinkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value ChainGinkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products Ginkgo Bioworks Advances Collaboration with Novo Nordisk on Expression Systems for Pharmaceutical Products LEARN MORE LEARN MORE LEARN MORE Jul. 2023Apr. 2024Sep. 2024Jun. 2022Oct. 2024 Expansion of the collaboration on expression systems for pharmaceutical products first announced in June 2022 Expansion of April 2024 partnership, focused on the discovery and development of proteins
Page 9
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —9"Ginkgo's achievement of the first milestone has both excited and inspired us, giving us the confidence to move into the next phase of this ambitious project. This progress is a strong indicator of the potential we have to engineer biological systems that will expand the chemical space of biological medicines."BRIAN VANDAHLSVP, Global Research Technologies LEARN MORE Ginkgo continued to deliver value and scientific breakthroughs across our pharma partnerships in 2024"We believe that Ginkgo’s unique combination of cell programming expertise, proprietary tools, and knowledge of biological systems make them an ideal collaboration partner to explore a large number of design ideas with the goal of optimizing constructs."ALPHONSE GALDESFmr. Head of Pharmaceutical Operations & TechnologyLEARN MORE "At Merck we are always seeking new and innovative ways to optimize process efficiency while maintaining product integrity," said Dr. Michael Kress, Senior Vice President, Development Sciences and Clinical Supply, Merck Research Laboratories. "We are pleased to build upon our relationship with the Ginkgo Bioworks team."MICHAEL KRESSSVP, Developmental Sciences & Clinical SupplyLEARN MORE "Access to Ginkgo's proprietary platform will help enable Pfizerto search for novel and exciting RNA constructs with improved stability and expression that could lead to more effective treatments."WILL SOMERSHead of Biomedicine DesignLEARN MORE
Page 10
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —101 2 3Restructuring in mid-2024 has greatly reduced cash opexGinkgo continues to grow our revenue in biopharmaExpansion into direct sales of life science tools & services is opening new markets for our transformational tech 10 We believe…
Page 11
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —11 Restructuring accomplishments to date Other expenses(overhead & program execution spending) PeopleSpace~$500M (1)Annualized, Run-Rate Cash Opex 1) Q1, Q2, and Q3 2024 R&D and G&A Expenses (excluding one-time M&A costs, stock-based compensation, depreciation & amortization, and non-cash lease expenses), respectively, multiplied by 4 ~$375M (1)Space● Transitioning out of several offices to reduce overall footprint● Boston area site consolidation complete by end of year, approximately 6 months ahead of schedulePeople● Previously announced headcount reduction of ~35%Other Expenses● Contractor and temp labor pool reduced by nearly 60%● Professional fees reduced by ~40% Q3 vs Q1● Significant reduction in software licenses and applications through strict rationalization ~$515M (1)
Page 12
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —12 Ginkgo is six months ahead of schedule in Site ConsolidationEvry Sold Altar SAS to Lesaffre including ALE entity in France. Transaction closed 9/30/2024.Zeist Site closure activities are underway. Tracking towards site closure by 12/1/2024.Boston / Cambridge Future footprint has been established. Move out of Cambridge sites (10 Wilson & 45 Moulton) is underway and expected to complete by 11/30/2024.Further consolidation in Drydock sites expected in Q1 2025. NYC (Patch Bio)430 E 29th180 Varick StClosed: 7/31/24Emeryville1440 Stanford5858 Horton West Sac850 Riverside890 EmbarcaderoZeist, NDLUltrechtseweg 48Site Closes: 12/1/24Boston / Cambridge✘1 ABP (Parcel O/P)21-25 Drydock23 Drydock27 Drydock451D✘10 WIlson✘45 MoultonCambridge Exit: 11/30/24✘✘Legend✘Exit Planned or CompletedSubleasedEvry, FRA5 Rue Henri DesbrueresTransition Ends: 12/31/24✘Basel, CHEHochbergerstrasse 60C
Page 13
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —13OUTLOOK as of Nov 12HISTORICALFY2024FY2023FY2022FY2021In millions of USDRevenue$165-185$144$144$113Cell Engineering$120-140$139$106$86Services-$4$38$27Downstream Value$45---Motif 3Q24 non-cash deferred revenue release$50+$108$334$201Biosecurity$215-235$251$478$314Total revenue Delivering on cell engineering and biosecurity revenue while undergoing major cost take-outs Reminder: Ginkgo updated guidance on Nov 12 earnings call solely to reflect the $45 million non-cash deferred revenue release
Page 14
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —141 2 3Restructuring in mid-2024 has greatly reduced cash opexGinkgo continues to grow our revenue in biopharmaExpansion into direct sales of life science tools & services is opening new markets for our transformational tech 14 We believe…
Page 15
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —15In 2024, we began offering our platform directly to customer scientists as tools, with IP owned by customer & simple customer-friendly business model.Ginkgo Platform CUSTOMER Scientific DeliverableSolutions Tools Head of R&DScientist
Page 16
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —16Ginkgo is expanding our cell engineering offerings into the life science tools and services space Research solutionsDatapointsAIAutomation Asset Licensing HIGHER LOWERService Fees OnlyService Fees + Royalties / MilestonesSOLUTIONS TOOLSSERVICE OFFERING GINKGO CUSTOMIZATION & TECH RISK Enables partners to optimize candidates to take forward into development and enable better manufacturing platformsEnable customer scientists to pursue high-throughput data generationProprietary lab automation workflows in customer facilitiesBuilds powerful tool designed to bring biological AI models directly to machine learning scientistsCell Engineering SolutionsCell Engineering Tools
Page 17
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —17Solutions and Tools are very complementary Research solutionsDatapointsAIAutomation Asset Licensing HIGHER LOWERService Fees OnlyService Fees + Royalties / MilestonesSOLUTIONS TOOLSSERVICE OFFERING GINKGO CUSTOMIZATION & TECH RISK Enables partners to optimize candidates to take forward into development and enable better manufacturing platformsEnable customer scientists to pursue high-throughput data generationProprietary lab automation workflows in customer facilitiesBuilds powerful tool designed to bring biological AI models directly to machine learning scientistsCell Engineering SolutionsCell Engineering Tools Large but slower potential upside with participation in customer’s products.Demonstrates the value of our entire tool chain to R&D leaders. Near term fee revenue and faster sales cycle. Exposes a much wider set of customers to our technology.
Page 18
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —18
Page 19
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —19[ GINKGO DATAPOINTS POWERS AI ]We built Ginkgo Datapoints to generate the data that underpins AI models in biotech. We provide data in a low-friction manner with your needs in mind. PricingBenefit from the economies of scale our automation offers with volume-based discounts. Deals are fee-for-service with no milestones or royalties.OwnershipYou own the data.PilotsWe can do small, nimble pilot deals to start. [ DEAL TERMS ] [ WAYS OF WORKING ]FlexibilityWe will carry out data generation campaigns to your needs, incl.:●Size of dataset●Cell lines & libraries●Assays & readouts●Flexible & secure data accessSpeedWe can return data in as little as 3 weeks.PartnershipOur highly skilled scientific team wants to collaborate with you.
Page 20
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —20The alliance will bring “AI, the lab, and the clinic together to uncover otherwise inaccessible patterns in vast quantities of data, and to design experiments to test those patterns.”AVIV REGEVHead of Genentech Research & Early Development (gRED), Global Research Technologies LEARN MORE“With AI in the loop today, we can get 80% of the value with 40% of the wet lab work, and that ratio will improve going forward.”BEN MABEYChief Technology OfficerLEARN MORE Appetite for these services is driven by interest in large data assets to enable AI in biotechnology
Page 21
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —21The Data Foundry model complements (does not replace!) a classic research approachClassic Research Approach Foundry Research ApproachFlexibilityInfinite LimitedData densityLow HighHypothesis-driven / focusedApproachInductive / broadComplementary approaches that feed innovationUse cases● Hypothesis testing● Proof of concept work● De-risking experiments● AI/ML model generation● Determining global maxima● Novel hypothesis generationBy-hand Robots, software, by-handExperimentsDo-it-all scientists Collaborating specialized teamsTeam
Page 22
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —22 Beyond our traditional Solutions offerings, we’ve also launched two Datapoints products LEARN MORE Choose from cell types, compound library, data readouts.Flexibility & CustomizationWe handle both perturbation and readouts. Tell us what you need, and we will deliver the data.End-to-End10,000s of in vitro chemical and genetic perturbations in each cell type.ScaleWe deliver data in as little as 3 weeks.SpeedFee-for-service only: no royalties, no milestones. And you own the data, always. Our version of an easy button.Attractive Deal Terms Signed deals with leading tech bio companies and top 10 biopharma companies
Page 23
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —23[ GINKGO DATAPOINTS FUNCTIONAL GENOMICS ]We can work with the cell types of your choosing Tissue / organSource organismCell typeLungHumanA549CervicalHumanHeLaKidneyHumanHEK293OsteosarcomaHumanU2 OSSkinHumanNormal Skin FibroblastsSkeletalHumanSkeletal MyoblastsAortaHumanVascular smooth muscleSkinHumanMelanocytesBloodHumanPBMCsBloodHumanTHP-1BloodHumanCAR T cellsLungHumanSmall Lung Airway EpithelialBrainHumaniPSC derived glutamatergic neuronsBrainHumanMicrogliaBladderHumanHT-1197BladderHuman5637BladderHumanHT-1376 Cell types onboarded on drug-seq Tissue / organSource organismCell lineColorectalHumanCaco-2ColorectalHumanHCT116LiverHumanHepG2IntestineHumanHIEC-6LiverHumanHuh7BreastHumanMCF7BrainHumanSk-N-ASIntestineHumanSW480BladderHumanT24BloodHumanJurkatBoneHumanRajiBone MarrowHumanK562EpithelialHumanARPE-19KidneyHumanExpi-293fKidneyHumanLentiX-293T Additional cell types onboarded on the Ginkgo platform Roadmap -to be onboarded by EOY…and many more! We have worked with ~100 human cell types
Page 24
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —24We released sample perturbation datasets to the public RELEASE DATE●December 2024DATA PACKAGE●Metadata for a subset of 10 compounds and all controls●PDF outlining the experimental set upCELL TYPES●Human melanocytes cells, aortic smooth muscle cells, dermal fibroblast, and skeletal muscle myoblastsPERTURBATIONS●85 compounds, 6 concentrations, 4 replicatesSEQUENCING DEPTH●2M readsREADOUT●Transcriptomic (Drug-seq)PLATE DENSITY●384-well plateAVAILABLE DATASET SIZE (FASTQ)●~200 GB / cell type RELEASE DATE●September 2024DATA PACKAGE●Metadata for the 1264 compounds screen●Raw UMI counts for the subset of 20 compounds●PDF outlining the experimental set upCELL TYPES●A459 cells (human non-small cell lung carcinoma, epithelial)PERTURBATIONS●1,264 compounds, 2 concentrations, 4 replicatesSEQUENCING DEPTH●2M readsREADOUT●Transcriptomic (Drug-seq)PLATE DENSITY●384-well plateAVAILABLE DATASET SIZE (FASTQ)●60 GB GDPx2 GDPx1Download sample datasets [ GINKGO DATAPOINTS FUNCTIONAL GENOMICS ]
Page 25
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —25 Beyond our traditional Solutions offerings, we’ve also launched two Datapoints products LEARN MORE ● Screen over 2,400 antibody sequences in parallel● Enabled by our highly automated lab and over $1 billion of invested wet lab infrastructureScaleChoose from 10+ developability assays across key biophysical antibody properties.BreadthScreen libraries including positive and negative sequences in standardized conditions and receive AI-ready data.AI-Ready Data● Combines decades of protein biophysics expertise with AI/ML-powered biological engineering ● Proprietary software accelerates automated data handling for faster insights● Supported by a dedicated AI team AI/ML Experience, Capabilities & ServicesFee-for-service only: no royalties, no milestones. And you own the data, always. Our version of an easy button.Simple & Easy Terms 1. We take your antibody sequences as input, perform wet lab workflows in high-throughput, and return AI-ready datasets as output2. We synthesize, express, and purify the antibodies, perform broad biophysical characterization, analyze and integrate the data3. Return an AI-ready dataset to you Deal signed with top 25 biopharma company
Page 26
Property of Ginkgo Bioworks —26GINKGO DATAPOINTS - ANTIBODY DEVELOPABILITY Standard Product Offering ReadyPartners select assays from our set of standard products Expanding to multiple antibody formats and assays to be responsive to customer needs [ GINKGO DATAPOINTS ANTIBODY DEVELOPABILITY ] Key Data OutputTechnologyAssaysCoremg/LValitaTiterKDOctetTarget Binding (BLI)%PurityLabChipFragmentation (CE-SDS)%HMW, %Monomer, ChromatogramHPLCAggregation (SE-HPLC)BiologicalKDLumit, BLIFcRn BindingRTHPLCHeparin BindingPSP score or RFUPSP or PAIAPolyspecificity (PSP)BiophysicalTm, TonsetnanoDSFThermostability (nanoDSF)ΔλmaxAuNP-basedSelf-Association (AC-SINS)kDDynaPro IIISelf-Interaction (DLS-kD)RT or RFUHPLC or PAIAHydrophobicity (HI-HPLC)RTHPLC Colloidal Stability (SMAC-HPLC) [ DEVELOPABILITY CHARACTERIZATION ] [ DELIVERABLE ]
Page 27
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —27We tailor data generation campaigns according to your R&D priorities and support cell types across multiple therapeutic areas Example 1: Data for Oncology Target ID [ Arrayed chemical perturbations incl. Drug-Seq readout ] Example 2: Data for Alzheimer’s Target ID [ Arrayed genetic perturbations (CRISPR-KO) incl. Drug-Seq + Imaging readout ]DRUG-SEQ:●Raw Fastq files●QC plot: total sequenced reads●QC plot: total reads mapped to reference●QC plot: percent of reads mapped to reference●QC plot: percent of rRNA removed before analysis●QC plot: number of genes recovered at >=3 UMIs●QC plot: PCA plot showing clustering between samples●UMI counts for all detected genesHIGH-CONTENT IMAGING●All .tiff images●QC plot: image quality●QC plot: plot of plate-based controls●QC plot: plot of all conditions testedData will be available via an AWS S3 bucket. Illustrative Deliverables[ PROJECT EXAMPLES ] DETAILS●Chemical Perturbations of 2,000 compounds in 5 different cancer cell types at 1 concentration*, incl. Drug-Seq ReadoutEXAMPLE CELL TYPES●A549, MCF-7, HCT116, HeLa, SK-MEL-28 and/or primary PBMCsTIMELINE●10-11 weeksDETAILS●Genetic Perturbations (CRISPR-KO) of 1,000 target genes across 3 cell types*, incl. Drug-Seq + Imaging readoutEXAMPLE CELL TYPES●CRISPR-ready, iPSC-derived neurons, astrocytes, and/or microgliaTIMELINE●9-10 weeks inclusive of time to design and order CRISPR KO guides* Assumptions: cells are Cas9-expressing and can be efficiently edited using Lipofectamine-based transduction * Assumptions: assumes 1 concentration in this example. Ginkgo can support several concentrations incl. dose response curves
Page 28
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —28 Additional options for a feeQCSequence DesignCustom cap, poly-A tailing, modified nucleotidesLNP packagingAdditional QC: Capping efficiency, dsRNA quantification, abortive transcriptionPurification: SPRI beadsPurity: 80-90%QC: UV-Vis + tape station5’ Cap1, 120 nt poly-A tailRegular, m1Ψ nucleotides High-throughput RNA data generationExtended duration, more protein Generate laboratory data to fine-tune and validate your mRNA sequence design modelsData generation assaysIncluded Options**DescriptionTAT / AssayThroughputHuh7 or HEK293T cell lines5’ UTR or 3’ UTR designsUp to 250 bpGinkgo standard payloadmRNA stability up to 72 hours3 months20,000 / assayStabilityPolysome fractionation profiling3 months20,000 / assayTranslationMultiple cell line optionsLuciferase or fluorescent proteinImage-based protein quantification2 months500 / weekProteinTHP1 or PBMCs10 targeted cytokinesCytokine panel2 months500 / weekImmune ResponsemRNA IVT specifications** Additional optionality (cell lines, in vivo contexts, therapeutic protein measurements, custom sequence designs) available for a fee. Please inquire with your project’s needs. RNA| HT Data Generation
Page 29
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —29
Page 30
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —30 HARDWAREReconfigurable Automation Carts (RACs) are building blocks for the automated labA RAC is a standardized enclosurefor integrating scientific instrumentation.Rigorously engineered hardware designed with industrial components improves the reliability of integrated lab equipment and allows for unparalleled scalability and flexibility. Optional HEPA FilterDedicated robotic arm improves reliability and throughput Utility routing(electrical, air, and data)Plate transport trackQuick connection points enable system reassembly in minutes, not daysLab deviceof choice, from any application or vendor
Page 31
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —31 Collections of RACs integrate to become RAC Systems
Page 32
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —32
Page 33
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —33 OFFERINGSOur Integrated OfferingHARDWARE Reconfigurable Automation Carts (RACs)Modular hardware building blocks that allow for (re)assembly of work cells within days or hours, not months.CATALYST SUBSCRIPTIONCatalyst ACSPowerful, modular, web-based software to control interconnected instruments and RACs Catalyst Flow 360-degree coverage, full-lifecycle, scalable support model that takes complete management responsibility for deployed automation systems. Enabled by our unique web-based architecture. HARDWARE CATALYST SUBSCRIPTION Reconfigurable Automation Carts (RACs) Catalyst ACS Automation Control Software Catalyst FlowManaged Automation Solution
Page 34
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —34 We hope RACs can become a horizontal platform to standardize integrated lab automation across the industry. Reconfigurable Automation Carts are “Lego” building blocks for Lab Automation
Page 35
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —35 Biology is captivating
Page 36
Ginkgo Bioworks — JP Morgan Healthcare — 2025 Property of Ginkgo Bioworks —36 ____________________Let’s grow the world we want to seejason@ginkgobioworks.com
Page 37
www.ginkgobioworks.com